title: Arabinoxylan consumption decreases postprandial serum glucose, serum insulin and plasma total ghrelin response in subjects with impaired glucose tolerance.
abstract: OBJECTIVE
  Arabinoxylan (AX) consumption is associated with metabolic improvement during diabetes and with modulation of ghrelin, an orexigenic gut hormone. The effect of AX consumption on ghrelin secretion in disturbed metabolic states is unknown. Therefore, we investigated the postprandial responses to AX consumption of serum glucose, insulin and triglycerides and plasma total and acylated ghrelin in subjects with impaired glucose tolerance (IGT).
  
  
  METHODS
  Randomized, single-blind, controlled, crossover intervention trial.
  
  
  METHODS
  Seven female and four male adults with IGT, aged 55.5 years, and body mass index (BMI) 30.1 kg/m(2).
  
  
  METHODS
  Subjects received either placebo or 15 g AX supplement for 6 weeks with a 6-week washout period in-between.
  
  
  METHODS
  Postprandial responses of serum glucose, insulin and triglycerides, and plasma total and acylated ghrelin after a liquid meal challenge test (LMCT) measured at the beginning and at the end of the dietary intervention at -20, -5, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210 and 240 min.
  
  
  RESULTS
  After LMCT, AX consumption resulted in lower postprandial responses in serum glucose, insulin and triglycerides (P<0.05). Compared to placebo, total plasma ghrelin was also reduced by 42+/-8 pg/ml (P<0.001) after AX consumption with no difference in plasma acylated ghrelin.
  
  
  CONCLUSIONS
  AX consumption improved postprandial metabolic responses after an LMCT in subjects with IGT and reduced total ghrelin response. However, acylated ghrelin responses were unchanged, suggesting that the acylated ghrelin-mediated orexigenic regulation is not improved as only total plasma ghrelin decreased.
authors.affiliation: Dietary Fibre and the Metabolic Syndrome Group, German Institute of Human Nutrition, Potsdam-Rehbruecke, Nuthetal, Germany.
authors.forename: A L
authors.initials: AL
authors.lastname: Garcia
authors.forename: B
authors.initials: B
authors.lastname: Otto
authors.forename: S-C
authors.initials: SC
authors.lastname: Reich
authors.forename: M O
authors.initials: MO
authors.lastname: Weickert
authors.forename: J
authors.initials: J
authors.lastname: Steiniger
authors.forename: A
authors.initials: A
authors.lastname: Machowetz
authors.forename: N N
authors.initials: NN
authors.lastname: Rudovich
authors.forename: M
authors.initials: M
authors.lastname: Möhlig
authors.forename: N
authors.initials: N
authors.lastname: Katz
authors.forename: M
authors.initials: M
authors.lastname: Speth
authors.forename: F
authors.initials: F
authors.lastname: Meuser
authors.forename: J
authors.initials: J
authors.lastname: Doerfer
authors.forename: H-J F
authors.initials: HJ
authors.lastname: Zunft
authors.forename: A H F
authors.initials: AH
authors.lastname: Pfeiffer
authors.forename: C
authors.initials: C
authors.lastname: Koebnick
mesh_terms: D000368:Aged; D019540:Area Under Curve; D001786:Blood Glucose / Q000378:metabolism*; D018592:Cross-Over Studies; D004043:Dietary Fiber / Q000008:administration & dosage*; D019587:Dietary Supplements; D005260:Female; D054439:Ghrelin; D018149:Glucose Intolerance / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D036361:Peptide Hormones / Q000097:blood*; D019518:Postprandial Period; D016037:Single-Blind Method; D012995:Solubility; D013997:Time Factors; D014280:Triglycerides / Q000097:blood; D014990:Xylans / Q000008:administration & dosage*
chemical_list: D001786:Blood Glucose; D004043:Dietary Fiber; D054439:Ghrelin; D007328:Insulin; D036361:Peptide Hormones; D014280:Triglycerides; D014990:Xylans; C085118:arabinoxylan